Novel p53-mdm2 and p53-mdm4 antagonists to treat proliferative diseases
- 詳細技術說明
- None
- *Abstract
-
Investigators at the University of Pittsburgh have developed small molecules targeting the interaction of p53 protein with both of its binding partners MDM2 and MDM4. This has resulted in a new generation of p53 mdm2 and mdmx antagonists with improved activity and anti cancer profile. Applications:* Treatment for cancer and other proliferative diseasesAdvantages:* Targeting p53 interactions with both of its binding partners MDM2 and MDM4 instead of only MDM2 PCT Patent Application filed
- *Principal Investigation
-
Name: Alexander Doemling
Department: Pharm-Pharmaceutical Science
Name: Tad Holak
Department:
- 國家/地區
- 美國
欲了解更多信息，請點擊 這裡
